Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

CartalaxvsBPC-157

Chondroprotective tripeptide bioregulator (Ala-Glu-Asp) that activates chondrogenic differentiation through SOX9/COL2A1/aggrecan upregulation, reverses senescence-associated secretory phenotype in aging chondrocytes, and provides geroprotective effects through SIRT-6 upregulation and p16/p21/p53 suppression

The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.

Anti-AgingHealing & Recovery

At a Glance

Quick
comparison

Dose Range

Cartalax

2–5 mg

BPC-157

250–500 mcg

Frequency

Cartalax

Once daily

BPC-157

Once daily

Administration

Cartalax

Oral (capsule)

BPC-157

Subcutaneous injection

Cycle Length

Cartalax

12+ weeks

BPC-157

4-6 weeks

Onset Speed

Cartalax

Gradual (3-4 weeks)

BPC-157

Moderate (1-2 weeks)

Evidence Level

Cartalax

Moderate human trials (Phase 1-2)

BPC-157

Strong preclinical (extensive animal studies)

Efficacy

Benefit
ratings

Cartalax
BPC-157

Anti-Aging

Cartalax8%
BPC-1570%

Healing & Recovery

Cartalax8%
BPC-1570%

Hormone Support

Cartalax6%
BPC-1570%

Primary Benefit

Cartalax0%
BPC-15785%

Secondary Benefit

Cartalax0%
BPC-15778%

Additional Benefit

Cartalax0%
BPC-15772%

Technical Data

Compound
specifications

Cartalax

Molecular Formula

C12H19N3O8

Molecular Weight

333.3 g/mol

Half-Life

Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids

Bioavailability

Orally bioavailable via intestinal peptide transporters (PepT1/PepT2, LAT1); 10-fold more potent than crude cartilage polypeptide complex at chondrogenic activation (200 vs 2000 ng/mL effective concentration)

CAS Number

Not yet registered (research compound)

BPC-157

Molecular Formula

C62H98N16O22

Molecular Weight

1419.53 g/mol

Half-Life

4-6 hours

Bioavailability

~100% (subcutaneous)

CAS Number

137525-51-0

Protocols

Dosing
tiers

Cartalax

starting

2-3 mg once daily

Once daily, morning

10 days initial assessment

Begin with the conservative starting protocol. Oral capsules taken before breakfast with water. The AED tripeptide is absorbed by intestinal peptide transporters (PepT1/PepT2). Effects are gradual — cartilage repair mechanisms take weeks to produce functional improvements. Do not expect pain relief during the initial period; Cartalax is not an analgesic.

standard

4-5 mg daily (divided doses)

1-2 times daily

10-20 days per treatment course

Standard clinical protocol. In Russian clinical practice, typical protocols use 20-day courses with intervals of 3-6 months. Can be combined with conventional OA treatments (physical therapy, joint support supplements). The epigenetic effects (SASP reversal, SIRT-6 upregulation) persist beyond the active treatment period. Track joint function, stiffness, and mobility to assess response over weeks to months.

advanced

6 capsules daily (as used in clinical studies)

Divided 2-3 times daily

20 days per course

Clinical study protocol used in Russian OA patients ages 52-72. Combined with conventional osteoarthritis treatment. This higher dose was used alongside standard therapy for patients with significant musculoskeletal pathology. Often combined with complementary Khavinson bioregulators: Sigumir for joint/bone support, Ventfort for vascular health, and Vilon for immune function. Repeat courses every 3-6 months.

BPC-157

starting

250 mcg

Once daily

1-2 weeks

Start here to assess tolerance. Can split into AM/PM if preferred.

standard

250-500 mcg

Twice daily

4-6 weeks

Most common protocol. Split doses morning and evening for best results.

advanced

500 mcg

Twice daily

6-8 weeks

For experienced users or severe injuries. Higher doses not shown to improve outcomes significantly.

Applications

Best
suited for

Cartalax

Cartilage regeneration and protection in age-related osteoarthritis

Cartalax is particularly well-suited for individuals focused on cartilage regeneration and protection in age-related osteoarthritis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Connective tissue repair and maintenance in aging individuals

Cartalax is particularly well-suited for individuals focused on connective tissue repair and maintenance in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue

Cartalax is particularly well-suited for individuals focused on geroprotective therapy targeting the sirt-6/senescence axis in musculoskeletal tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy

Cartalax is particularly well-suited for individuals focused on complementing conventional osteoarthritis treatments with bioregulatory peptide therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

BPC-157

Tendon and ligament injuries

Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair

Gut healing

IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue

Muscle injuries

Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression

Joint problems

Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties

Post-surgical recovery

Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms

Safety Profile

Side
effects

Cartalax

Common

  • Mild injection site reaction
  • Mild GI discomfort
  • Mild fatigue
  • Transient joint stiffness

Uncommon

  • Temporary increase in joint discomfort

Serious

  • No documented serious adverse effects

BPC-157

Common

  • Injection site redness
  • Mild nausea
  • Dizziness

Uncommon

  • Headache
  • Fatigue
  • Hot/cold sensations

Serious

  • Allergic reaction

Research Status

Safety
& evidence

Cartalax

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.

Contraindications

  • xKnown hypersensitivity to peptide bioregulators or constituent amino acids (alanine, glutamic acid, aspartic acid)
  • xPregnancy and breastfeeding — insufficient reproductive safety data
  • xActive joint infection — treat infection before initiating peptide bioregulator therapy
  • xMalignant bone or cartilage tumors — proliferative effects of peptide bioregulators may be contraindicated

BPC-157

Evidence Level

Strong preclinical (extensive animal studies)

FDA Status

Research compound

Safety Overview

BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.

Contraindications

  • xPregnancy
  • xBreastfeeding
  • xActive cancer
  • xHistory of cancer

Decision Guide

Which is
right for you?

Choose Cartalax if...

  • Cartilage regeneration and protection in age-related osteoarthritis
  • Connective tissue repair and maintenance in aging individuals
  • Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
  • Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy

Choose BPC-157 if...

  • Injury recovery
  • Post-surgery healing
  • Chronic pain management
  • Gut health